The global PD-L1 biomarker testing market is on a strong growth trajectory, rising from USD 777.2 million in 2025 to USD 1,690.8 million by 2035, at a CAGR of 8.1% during the forecast period. PD-L1 ...
Dublin, March 06, 2025 (GLOBE NEWSWIRE) -- The "PD-L1 Biomarker Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ResearchAndMarkets ...
EINPresswire/ -- "Get 20% Off All Global Market Reports With Code ONLINE20 – Stay Ahead Of Trade Shifts, Macroeconomic Trends, And Industry Disruptors What Is The Expected Cagr For The PD-L1 And ...
GUILDFORD, UK / ACCESSWIRE / November 9, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in ...
MONMOUTH JUNCTION, N.J., March 12, 2025 /PRNewswire/ -- Researchers from Creatv Bio, Division of Creatv MicroTech, Inc. (Monmouth Junction, NJ) and The Mayo Clinic (Jacksonville, FL), in collaboration ...
SANTA CLARA, Calif. - Agilent Technologies Inc. (NYSE: A), a $29.3 billion market cap company with a robust 54% gross profit margin, has announced that its PD-L1 IHC 22C3 pharmDx assay has received ...
During a live event, Yelena Y. Janjigian, MD, moderated a discussion on how to use PD-L1 CPS status when considering ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback